Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist.
Ran Zhu, Ashley H Snyder, Yugesh Kharel, Lisa Schaffter, Qin Sun, Perry C Kennedy, Kevin R Lynch, Timothy L Macdonald
Index: J. Med. Chem. 50(25) , 6428-35, (2007)
Full Text: HTML
Abstract
Compound 1 (FTY720, Fingolimod) represents a new generation of immunosuppressant that modulates lymphocyte trafficking by interacting with the S1P(1) receptor. Compound 1 also provides a template molecule for studying the molecular biology of S1P receptors and related enzymes (kinases and phosphatases). In this study, two conformationally constrained analogues of 1 ( 3a and 3c) were asymmetrically synthesized in high optical purity. In vitro assessment documented that both analogues are Sphk2 substrates, their phosphorylated species are potent S1P(1) receptor agonists, and 3a-P is a potent S1P 3 antagonist. After oral administration in mice, both compounds evoked lymphopenia, but their duration of action differed markedly.
Related Compounds
Related Articles:
Kinetic studies of the homogeneous abiotic reactions of several chlorinated aliphatic compounds in aqueous solution. Pagan M, et al.
[Appl. Geochem. 13(6) , 779-85, (1998)]
Derivatives of phosphorus acids and 2-chloro-2-propen-1-ol. Arbuzov BA, et al.
[Russ. Chem. Bull. 16(6) , 1233-38, (1967)]
Photofragment imaging study of the CH2CCH2OH radical intermediate of the OH+allene reaction.
2007-10-21
[J. Chem. Phys. 127(15) , 154316, (2007)]
Degradation of 2-chloroallylalcohol by a Pseudomonas sp.
1993-02-01
[Appl. Environ. Microbiol. 59(2) , 528-35, (1993)]